Riskpilot← Back to searchSign inGet full accessENDOTECH AS
ASActiveOrg 958103425Snarøyveien 36, 1364 FornebuWholesale of pharmaceutical and medical goods · NACE 4646Est. 199015 employeeswww.endotech.no
Revenue 2025
NOK 133M
+67% vs 2024
EBITDA margin
16.3%
+193% vs 2024
Equity ratio
34.3%
Financial strength
Net profit 2025
NOK 14,9M
+236% vs 2024
| Revenue | NOK 133M | +67% |
| EBITDA | NOK 21,7M | +193% |
| Net profit | NOK 14,9M | +236% |
| Total assets | NOK 63M | +36% |
| Equity | NOK 21,6M | +207% |
| Employees | 15 | — |
Legal name
ENDOTECH AS
Org number
958103425
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. april 1990
Share capital
NOK 1 075 200
Employees
15 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Address
Snarøyveien 36, 1364 Fornebu
Website
www.endotech.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15 590 | 17 410 | 20 129 | 21 395 | 22 142 | 22 875 | 24 499 | 27 418 | 33 613 | 36 237 | 39 399 | 41 081 | 79 879 | 65 332 | 62 413 | 67 946 | 79 470 | 133 010 |
| Staff expenses | −4 350 | −4 173 | −4 569 | −4 931 | −5 199 | −5 795 | −6 342 | −6 887 | −7 887 | −9 338 | −9 742 | −10 379 | −11 671 | −12 646 | −13 476 | −14 345 | −15 523 | −19 718 |
| EBITDA | 1 112 | 1 195 | 2 670 | 3 250 | 1 301 | 1 809 | 1 888 | 1 947 | 3 202 | 2 673 | 3 529 | 2 955 | 10 859 | 7 634 | 2 077 | 4 227 | 7 407 | 21 666 |
| Depreciation & amort. | −297 | −233 | −421 | −511 | −528 | −316 | −107 | −96 | −82 | −95 | −335 | −363 | −479 | −184 | −158 | −424 | −134 | −1 243 |
| EBIT | 815 | 962 | 2 249 | 2 740 | 773 | 1 493 | 1 781 | 1 851 | 3 120 | 2 578 | 3 194 | 2 592 | 10 379 | 7 450 | 1 918 | 3 803 | 7 274 | 20 424 |
| Net financials | −233 | −15 | −290 | −419 | −197 | −420 | −640 | −310 | 27 | −17 | −447 | −185 | −539 | −331 | −133 | −874 | −1 538 | −1 185 |
| Profit before tax | 582 | 947 | 1 959 | 2 320 | 576 | 1 073 | 1 140 | 1 541 | 3 147 | 2 561 | 2 747 | 2 407 | 9 840 | 7 119 | 1 785 | 2 929 | 5 735 | 19 239 |
| Tax | 315 | 330 | 655 | 709 | 252 | 328 | 382 | 435 | 862 | 719 | 685 | 599 | 2 226 | 1 602 | 487 | 641 | 1 320 | 4 384 |
| Net profit | 267 | 617 | 1 304 | 1 611 | 324 | 745 | 758 | 1 106 | 2 285 | 1 842 | 2 062 | 1 808 | 7 615 | 5 517 | 1 298 | 2 288 | 4 415 | 14 855 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 7 903 | 8 415 | 10 799 | 10 852 | 11 114 | 10 519 | 10 783 | 12 725 | 14 031 | 13 993 | 15 480 | 14 009 | 29 027 | 28 347 | 23 992 | 29 594 | 46 344 | 63 020 |
| Equity | 2 040 | 2 257 | 2 561 | 2 871 | 2 548 | 2 693 | 3 151 | 3 357 | 4 242 | 3 985 | 4 247 | 5 454 | 6 627 | 8 314 | 9 693 | 1 295 | 7 030 | 21 588 |
| Long-term debt | 2 950 | 2 491 | 3 431 | 3 172 | 4 841 | 3 257 | 1 595 | 1 395 | 1 606 | 178 | 1 244 | 916 | 815 | 325 | 1 000 | 1 438 | 16 390 | 0 |
| Short-term debt | 2 914 | 3 667 | 4 807 | 4 809 | 3 725 | 4 569 | 6 037 | 7 972 | 8 183 | 9 830 | 9 990 | 7 638 | 21 584 | 19 708 | 13 298 | 26 861 | 22 924 | 41 228 |
| Total debt | 5 864 | 6 159 | 8 238 | 7 981 | 8 566 | 7 825 | 7 632 | 9 368 | 9 789 | 10 009 | 11 234 | 8 555 | 22 400 | 20 033 | 14 298 | 28 299 | 39 314 | 41 433 |
EBITDA margin
16.3%
This company
15.8%
Market median
+3% vs market
20082025
Equity ratio
34.3%
This company
38.2%
Market median
+10% vs market
20082025
Return on equity
68.8%
This company
18.4%
Market median
+274% vs market
20082025
Net profit margin
11.2%
This company
8.1%
Market median
+38% vs market
20082025
Asset turnover
2.11×
This company
1.12×
Market median
+88% vs market
20082025
Debt / equity
1.92×
This company
0.62×
Market median
-210% vs market
20082025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
DN Chief Executive Officer | Chief Executive Officer | 2001 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2026 | — | — | |
| Board of Directors | 2026 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2024 | — | — | |
| Chairman | 2026 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nordic Medical Group As | Company | 95.0% | 95.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Da-No Holding As
ENDOTECH AS Board members of ENDOTECH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Dag Nord | Chief Executive Officer | 0 companies |
| Jørgen Lindberg | Board of Directors | 0 companies |
| Torkild Stenbock | Chairman | 0 companies |
| Anders Rabben Kjøde | Board of Directors | 0 companies |
| Rune Martini | Chairman | 0 companies |
| Lars Petter Waldø-Jensen | Chairman | 0 companies |
| Trond Dahl Hansen | Chairman | 0 companies |